metadata
tags:
- sentence-transformers
- sentence-similarity
- feature-extraction
- generated_from_trainer
- dataset_size:216
- loss:MatryoshkaLoss
- loss:MultipleNegativesRankingLoss
base_model: Snowflake/snowflake-arctic-embed-l
widget:
- source_sentence: >-
What types of organizations are eligible to apply for the PAR-25-353
opportunity titled "National Cooperative Drug/Device Discovery/Development
Groups (NCDDG) for the Treatment of Mental Disorders"?
sentences:
- "PAR-25-353: National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional) Section III. Eligibility Information\n \n \n \n \n 1. Eligible Applicants\n \n \n \n Eligible Organizations\n \n Higher Education Institutions\n \n \n \n Public/State Controlled Institutions of Higher Education\n \n \n Private Institutions of Higher Education\n \n \n \n The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:\n \n \n \n Hispanic-serving Institutions\n \n \n Historically Black Colleges and Universities (HBCUs)\n \n \n Tribally Controlled Colleges and Universities (TCCUs)\n \n \n Alaska Native and Native Hawaiian Serving Institutions\n \n \n Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)\n \n \n \n Nonprofits Other Than Institutions of Higher Education\n \n \n \n Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)\n \n \n Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)\n \n \n \n For-Profit Organizations\n \n \n \n Small Businesses\n \n \n For-Profit Organizations (Other than Small Businesses)\n \n \n \n Local Governments\n \n \n \n State Governments\n \n \n County Governments\n \n \n City or Township Governments\n \n \n Special District Governments\n \n \n Indian/Native American Tribal Governments (Federally Recognized)\n \n \n Indian/Native American Tribal Governments (Other than Federally Recognized)\n \n \n \n \n \n Federal Governments\n \n \n \n Eligible Agencies of the Federal Government\n \n \n U.S. Territory or Possession\n \n \n \n \n \n Other\n \n \n \n Independent School Districts\n \n \n Public Housing Authorities/Indian Housing Authorities\n \n \n Native American Tribal Organizations (other than Federally recognized tribal governments)\n \n \n Faith-based or Community-based Organizations\n \n \n Regional Organizations\n \n \n \n \n Foreign Organizations\n \n \n \n Non-domestic (non-U.S.) Entities (Foreign Organization)\n \n are not\n \n eligible to apply.\n \n \n \n \n Non-domestic (non-U.S.) components of U.S. Organizations\n \n are not\n \n eligible to apply.\n \n \n \n \n Foreign components, as\n \n defined in the NIH Grants Policy Statement\n \n ,\n \n are\n \n allowed.\n \n \n \n Required Registrations\n \n \n Applicant organizations\n \n \n \n Applicant organizations must complete and maintain the following registrations as described in the\n \n How to Apply- Application Guide\n \n to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference\n \n NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications\n \n for additional information.\n \n \n \n \n System for Award Management (SAM)\n \n – Applicants must complete and maintain an active registration,\n \n which requires renewal at least annually\n \n . The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.\n \n \n \n NATO Commercial and Government Entity (NCAGE) Code\n \n – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.\n \n \n Unique Entity Identifier (UEI) - A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.\n \n \n \n \n \n eRA Commons\n \n - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their Grants.gov registration; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.\n \n \n \n Grants.gov\n \n – Applicants must have an active SAM registration in order to complete the Grants.gov registration.\n \n \n \n \n Program Directors/Principal Investigators (PD(s)/PI(s))\n \n \n \n All PD(s)/PI(s) must have an eRA Commons account. \_PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.\n \n \n \n Eligible Individuals (Program Director/Principal Investigator)\n \n Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support.\n \n \n For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the\n \n How to Apply - Application Guide\n \n .\n \n \n \n \n An NIH intramural scientist may not serve as the PD/PI of an NCDDG but may participate as a research collaborator or consultant (see\n \n \n \n Section IV.7\n \n \n \n for more information).\n \n \n \n \n 2. Cost Sharing\n \n \n This NOFO does not require cost sharing as defined in the\n \n NIH Grants Policy Statement\n \n \n Section 1.2- Definitions of Terms.\n \n \n \n \n \n 3. Additional Information on Eligibility\n \n \n Number of Applications\n \n \n \n \n Applicant organizations may submit more than one application, provided that each application is scientifically distinct.\n \n \n The NIH will not accept duplicate or highly overlapping applications under review at the same time per\n \n NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application\n \n . This means that the NIH will not accept:\n \n \n \n A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.\n \n \n A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.\n \n \n An application that has substantial overlap with another application pending appeal of initial peer review (see\n \n NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications\n \n )."
- "RFA-DK-26-009: New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed) Section VI. Award Administration Information\n \n \n \n \n 1. Award Notices\n \n \n A Notice of Award (NoA) is the official authorizing document notifying the applicant that an award has been made and that funds may be requested from the designated HHS payment system or office. The NoA is signed by the Grants Management Officer and emailed to the recipient’s business official.\n \n \n In accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.\n \n \n Recipients must comply with any funding restrictions described in\n \n Section IV.6. Funding Restrictions\n \n . Any pre-award costs incurred before receipt of the NoA are at the applicant's own risk. \_For more information on the Notice of Award, please refer to the\n \n NIH Grants Policy Statement Section 5. The Notice of Award\n \n and NIH Grants & Funding website, see\n \n Award Process.\n \n \n \n \n \n Institutional Review Board or Independent Ethics Committee Approval: Recipient institutions must ensure that protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.\n \n \n \n \n 2. Administrative and National Policy Requirements\n \n \n The following Federal wide and HHS-specific policy requirements apply to awards funded through NIH:\n \n \n \n The rules listed at\n \n 2 CFR Part 200\n \n , Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards.\n \n \n All NIH grant and cooperative agreement awards include the\n \n NIH Grants Policy Statement\n \n as part of the terms and conditions in the Notice of Award (NoA). The NoA includes the requirements of this NOFO. For these terms of award, see the\n \n NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General\n \n and\n \n Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Recipients, and Activities\n \n .\n \n \n If a recipient receives an award, the recipient must follow all applicable nondiscrimination laws. The recipient agrees to this when registering in SAM.gov. The recipient must also submit an Assurance of Compliance (\n \n HHS-690\n \n ). To learn more, see the\n \n Laws and Regulations Enforced by the\_HHS Office for Civil Rights website\n \n .\n \n \n HHS recognizes that NIH research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this NOFO.\n \n \n \n \n \n All federal statutes and regulations relevant to federal financial assistance, including those highlighted in\n \n NIH Grants Policy Statement Section 4 Public Policy Requirements, Objectives and Other Appropriation Mandates.\n \n \n \n Recipients are responsible for ensuring that their activities comply with all applicable federal regulations.\_ NIH may terminate awards under certain circumstances.\_ See\n \n 2 CFR Part 200.340 Termination\n \n and\n \n NIH Grants Policy Statement Section 8.5.2 Remedies for Noncompliance or Enforcement Actions: Suspension, Termination, and Withholding of Support\n \n .\n \n \n Successful recipients under this NOFO agree that:\n \n \n Where the award funding involves implementing, acquiring, or upgrading health IT for activities by any funded entity, recipients and subrecipient(s) are required to: Use health IT that meets standards and implementation specifications adopted in 45 CFR part 170, Subpart B, if such standards and implementation specifications can support the activity.\_ Visit\n \n https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-D/part-170/subpart-B\n \n to learn more.\n \n \n Where the award funding involves implementing, acquiring, or upgrading health IT for activities by eligible clinicians in ambulatory settings, or hospitals, eligible under Sections 4101, 4102, and 4201 of the HITECH Act, use health IT certified under the ONC Health IT Certification Program if certified technology can support the activity. Visit\n \n https://www.healthit.gov/topic/certification-ehrs/certification-health-it\n \n to learn more.\n \n \n Pursuant to the Cybersecurity Act of 2015, Div. N, § 405, Pub. Law 114-113, 6 USC § 1533(d), the HHS Secretary has established a common set of voluntary, consensus-based, and industry-led guidelines, best practices, methodologies, procedures, and processes.\n \n \n Successful recipients under this NOFO agree that:\n \n \n When recipients, subrecipients, or third-party entities have:\n \n \n \n ongoing and consistent access to HHS owned or operated information or operational technology systems; and\n \n \n receive, maintain, transmit, store, access, exchange, process, or utilize personal identifiable information (PII) or personal health information (PHI) obtained from the awarding HHS agency for the purposes of executing the award.\n \n \n \n Recipients shall develop plans and procedures, modeled after the\n \n NIST Cybersecurity framework\n \n , to protect HHS systems and data. Please refer to\n \n NIH Post-Award Monitoring and Reporting\n \n for additional information.\n \n \n \n Cooperative Agreement Terms and Conditions of Award\n \n Not Applicable.\n \n \n \n 3. Data Management and Sharing\n \n Consistent with the 2023 NIH Policy for Data Management and Sharing, when data management and sharing is applicable to the award, recipients will be required to adhere to the Data Management and Sharing requirements as outlined in the\n \n NIH Grants Policy Statement\n \n . Upon the approval of a Data Management and Sharing Plan, it is required for recipients to implement the plan as described.\n \n \n \n \n 4. Reporting\n \n \n When multiple years are involved, recipients will be required to submit the\n \n Research Performance Progress Report (RPPR)\n \n annually and financial statements as required in the\n \n NIH Grants Policy Statement Section 8.4.1 Reporting.\n \n To learn more about post-award monitoring and reporting, see the NIH Grants & Funding website, see\n \n Post-Award Monitoring and Reporting\n \n .\n \n \n \n \n A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the\n \n NIH Grants Policy Statement Section 8.6 Closeout\n \n . NIH NOFOs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 2 CFR Part 200.301."
- "RFA-HL-26-011: Leadership and Coordination Center (LACC) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed) Section II. Award Information\n \n \n \n Funding Instrument\n \n Cooperative Agreement: A financial assistance mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this NOFO.\n \n \n \n Application Types Allowed\n New\n \n \n \n \n The\n \n OER Glossary\n \n and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.\n \n \n \n Clinical Trial?\n \n Not Allowed: Only accepting applications that do not propose clinical trials.\n \n \n \n \n \n Need help determining whether you are doing a clinical trial?\n \n \n \n \n Funds Available and Anticipated Number of Awards\n \n The following NIH components intend to commit an estimated total of $3 million to fund a single award in FY 2026:\n \n \n NHLBI,\_$1.37 million\n \n \n NIAID, $0.30 million\n \n \n NIMH,\_$0.30 million\n \n \n NCI, $0.35 million\n \n \n NIA, $0.19 million\n \n \n NIDA, $0.15 million\n \n \n NICHD, $0.13 million\n \n \n NIDCR,\_$0.07 million\n \n \n NIMHD, $0.04 million\n \n \n NIAAA,\_$0.03 million\n \n \n NINR,\_$0.03 million\n \n \n ORWH, $0.03 million\n \n \n NIDCD,\_$0.02 million\n \n \n \n Award Budget\n \n Application budgets may not exceed direct costs of $2 million per year in Fiscal Years 2026 through 2031.\n \n \n \n Award Project Period\n \n 6 years\n \n This variable defines that we need to start a new row. \n \n \n \n NIH grants policies as described in the\n \n NIH Grants Policy Statement\n \n will apply to the applications submitted and awards made from this NOFO."
- source_sentence: >-
How does the title of opportunity ID [insert ID] align with the strategic
goals of the Department of Health and Human Services?
sentences:
- Department of Health and Human Services
- >-
RFA-DK-26-007: Collaborative Research Using Biosamples and/or Data from
Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)
Section II. Award Information
Funding Instrument
Grant: A financial assistance mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.
Application Types Allowed
New
Resubmission - Resubmission applications from
RFA-DK-22-021
and from the current active NOFO RFA-DK-26-007 may be submitted in response to this NOFO.
The
OER Glossary
and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
Clinical Trial?
Not Allowed: Only accepting applications that do not propose clinical trials.
Need help determining whether you are doing a clinical trial?
Funds Available and Anticipated Number of Awards
NIDDK intends to commit $5.5 million in Fiscal Year 2026 to fund 3-4 awards and $5.5 million in FY 27 to fund 3-4 awards. The number of awards is contingent upon the submission of a sufficient number of meritorious applications.
Award Budget
Application budgets are limited to no more than $1,200,000 direct costs per year, exclusive of facilities and administrative (F&A) costs. Budgets are expected to reflect the actual needs of the proposed project.
Award Project Period
The maximum project period is 3 years.
This variable defines that we need to start a new row.
NIH grants policies as described in the
NIH Grants Policy Statement
will apply to the applications submitted and awards made from this NOFO.
- "RFA-DK-26-009: New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed) Section IV. Application and Submission Information\n \n \n \n \n 1. Requesting an Application Package\n \n \n The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution.\n \n \n \n \n 2. Content and Form of Application Submission\n \n \n It is critical that applicants follow the instructions in the Research (R) Instructions in the\n \n How to Apply - Application Guide\n \n except where instructed in this notice of funding opportunity to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.\n \n \n \n \n Letter of Intent\n \n \n Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.\n \n \n By the date listed in\n \n Part 1. Overview Information\n \n , prospective applicants are asked to submit a letter of intent that includes the following information:\n \n \n \n Descriptive title of proposed activity\n \n \n Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)\n \n \n Names of other key personnel\n \n \n Participating institution(s)\n \n \n Number and title of this funding opportunity\n \n \n \n The letter of intent should be sent to:\n \n \n John Connaughton, Ph.D.\n \n Chief, Scientific Review Branch\n \n National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\n \n Telephone: 301-594-7797\n \n Email:\n \n \n [email\_protected]\n \n \n \n \n \n \n Page Limitations\n \n \n All page limitations described in the\n \n How to Apply- Application Guide\n \n and the\n \n Table of Page Limits\n \n must be followed.\n \n \n \n Instructions for Application Submission\n \n The following section supplements the instructions found in the\n \n How to Apply- Application Guide\n \n and should be used for preparing an application to this NOFO.\n \n \n \n \n SF424(R&R) Cover\n \n \n All instructions in the\n \n \n How to Apply - Application Guide\n \n \n must be followed.\n \n \n \n \n SF424(R&R) Project/Performance Site Locations\n \n \n All instructions in the How to Apply- Application Guide must be followed.\n \n \n \n \n SF424(R&R) Other Project Information\n \n \n All instructions in the How to Apply- Application Guide must be followed.\n \n \n \n \n \n Other Attachments:\n \n \n \n \n Proposed Affiliation Letter\n \n : Name the PDF formatted letter \"Proposed_Affiliation_Ltr.pdf\". Applications must include a one page letter that includes a brief statement identifying the specific NIDDK consortium or network that is within scope of the proposed aims. In addition, the applicant must outline in the letter how the objectives and design of the application\_are related to, but distinct from, ongoing studies in the consortium or network of interest, and describe how developing a relationship with the chosen consortium or network would be expected to facilitate the applicant's research and career goals. Applications that lack the proposed Affiliation Letter are considered incomplete and will not be peer reviewed.\n \n \n \n \n SF424(R&R) Senior/Key Person Profile\n \n \n All instructions in the How to Apply- Application Guide must be followed.\n \n \n \n \n R&R or Modular Budget\n \n \n All instructions in the How to Apply- Application Guide must be followed.\n \n \n \n \n Applicants should also follow these additional instructions:\n \n \n Applicants should budget for travel to one meeting of the proposed affiliated consortium or network per year. Except in unusual circumstances, only the PD/PI may be supported by R03 funds to travel to consortium meetings. There is no specific line item in which to list travel costs ($2000/year) in the modular budget format; instead, the proposed travel should be described in the budget justification section.\n \n \n \n \n R&R Subaward Budget\n \n \n All instructions in the How to Apply-Application Guide must be followed.\n \n \n \n \n PHS 398 Cover Page Supplement\n \n \n All instructions in the How to Apply- Application Guide must be followed.\n \n \n \n \n PHS 398 Research Plan\n \n \n All instructions in the How to Apply- Application Guide must be followed, with the following additional instructions:\n \n \n \n \n \n Resource Sharing Plan\n \n :\_Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the How to Apply- Application Guide.\n \n \n \n \n \n Protocol, tool and reagent sharing\n \n : The applicant should discuss plans for sharing and distribution of non-data resources that will be generated by the proposed project, including models, protocols, computational tools, biomaterials, and reagents. As one of the essential goals of the Gateway\_program is to support high impact\_advances, NIDDK intends that tools and reagents generated by the Gateway\_program will be made broadly available and distributed at minimal cost, and without undue intellectual property constraints, so that they can be as widely used as possible, thus enabling rapid downstream applications for the reagents by the larger scientific community. Applicants are expected to register resources supported by this NOFO with the NIDDK Information Network (dkNET) at\n \n https://dknet.org/\n \n and use Research Resource Identifiers (RRID) assigned through dkNET in any publication supported by this NOFO. Applicants should also be familiar with the NIH statements regarding intellectual property of resources developed with Federal funds\n \n (\n \n NIH Research Tools Policy (\n \n \n https://grants.nih.gov/grants/intell-property_64FR72090.pdf\n \n \n ) and other related NIH sharing policies at\n \n \n http://sharing.\n \n nih.gov\n \n .\n \n \n \n \n \n Other Plan(s):\n \n \n \n All instructions in the How to Apply-Application Guide must be followed, with the following additional instructions:\n \n \n \n \n \n All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan.\n \n \n \n \n \n \n Appendix:\n \n Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the How to Apply- Application Guide.\n \n \n \n No publications or other material, with the exception of blank questionnaires or blank surveys, may be included in the Appendix.\n \n \n \n \n \n PHS Human Subjects and Clinical Trials Information\n \n \n When involving human subjects research, clinical research, and/or NIH-defined\_clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the How to Apply- Application Guide, with the following additional instructions:\n \n \n If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the\n \n Study Record: PHS Human Subjects and Clinical Trials Information\n \n form or\n \n Delayed Onset Study\n \n record.\n \n \n \n Study Record: PHS Human Subjects and Clinical Trials Information\n \n \n \n All instructions in the How to Apply- Application Guide must be followed.\n \n \n \n \n \n Delayed Onset Study\n \n \n \n Note:\n \n Delayed onset\n \n does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the How to Apply- Application Guide must be followed.\n \n \n \n \n PHS Assignment Request Form\n \n \n All instructions in the How to Apply- Application Guide must be followed.\n \n \n \n \n 3. Unique Entity Identifier and System for Award Management (SAM)\n \n \n See Part 2. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov\n \n \n \n \n 4. Submission Dates and Times\n \n \n Part I.\_contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or\n \n Federal holiday\n \n , the application deadline is automatically extended to the next business day.\n \n \n Organizations must submit applications to\n \n Grants.gov\n \n (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the\n \n eRA Commons\n \n , NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. \_If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the\n \n NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications\n \n .\n \n \n \n Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.\n \n \n \n Information on the submission process and a definition of on-time submission are provided in the How to Apply-Application Guide.\n \n \n \n \n 5. Intergovernmental Review (E.O. 12372)\n \n \n This initiative is not subject to\n \n intergovernmental review.\n \n \n \n \n \n 6. Funding Restrictions\n \n \n All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the\n \n NIH Grants Policy Statement\n \n .\n \n \n Pre-award costs are allowable only as described in the\n \n NIH Grants Policy Statement Section 7.9.1 Selected Items of Cost.\n \n \n \n \n 7. Other Submission Requirements and Information\n \n Applications must be submitted electronically following the instructions described in the How to Apply Application Guide. Paper applications will not be accepted.\n \n \n Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.\n \n \n For assistance with your electronic application or for more information on the electronic submission process, visit\n \n How to Apply – Application Guide\n \n . If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the\n \n Dealing with System Issues\n \n guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.\n \n \n \n Important reminders:\n \n \n \n All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form\n \n .\n \n Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this NOFO for information on registration requirements.\n \n \n The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the How to Apply Application Guide.\n \n \n See\n \n more tips\n \n for avoiding common errors.\n \n \n \n \n Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by NIDDK. \_Applications that are incomplete, non-compliant, and/or nonresponsive will not be reviewed.\n \n \n \n Mandatory Disclosure\n \n Recipients or subrecipients must submit any information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. See Mandatory Disclosures,\n \n 2 CFR 200.113\n \n and\n \n NIH Grants Policy Statement Section 4.1.35\n \n .\n \n \n Send written disclosures to the NIH Chief Grants Management Officer listed on the Notice of Award for the IC that funded the award and to the\n \n HHS Office of Inspector Grant Self Disclosure Program\n \n at\n \n \n [email\_protected]\n \n \n .\n \n \n \n \n Post Submission Materials\n \n \n Applicants are required to follow the instructions for post-submission materials, as described in\n \n the policy"
- source_sentence: >-
What are the main objectives of the Leadership and Coordination Center
(LACC) for the MACS/WIHS Combined Cohort Study (MWCCS) as outlined in
opportunity id RFA-HL-26-011?
sentences:
- >-
RFA-HL-26-011: Leadership and Coordination Center (LACC) for the
MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not
Allowed) Part 2. Full Text of Announcement
- >-
PAR-25-353: National Cooperative Drug/Device Discovery/Development
Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial
Optional) Section VIII. Other Information
Recently issued trans-NIH
policy notices
may affect your application submission. A full list of policy notices published by NIH is provided in the
NIH Guide for Grants and Contracts
. All awards are subject to the terms and conditions, cost principles, and other considerations described in the
NIH Grants Policy Statement
.
Authority and Regulations
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
end row
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Department of Health
and Human Services (HHS)
NIH... Turning Discovery Into Health
®
- "PAR-25-353: National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional) Section III. Eligibility Information\n \n \n \n \n 1. Eligible Applicants\n \n \n \n Eligible Organizations\n \n Higher Education Institutions\n \n \n \n Public/State Controlled Institutions of Higher Education\n \n \n Private Institutions of Higher Education\n \n \n \n The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:\n \n \n \n Hispanic-serving Institutions\n \n \n Historically Black Colleges and Universities (HBCUs)\n \n \n Tribally Controlled Colleges and Universities (TCCUs)\n \n \n Alaska Native and Native Hawaiian Serving Institutions\n \n \n Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)\n \n \n \n Nonprofits Other Than Institutions of Higher Education\n \n \n \n Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)\n \n \n Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)\n \n \n \n For-Profit Organizations\n \n \n \n Small Businesses\n \n \n For-Profit Organizations (Other than Small Businesses)\n \n \n \n Local Governments\n \n \n \n State Governments\n \n \n County Governments\n \n \n City or Township Governments\n \n \n Special District Governments\n \n \n Indian/Native American Tribal Governments (Federally Recognized)\n \n \n Indian/Native American Tribal Governments (Other than Federally Recognized)\n \n \n \n \n \n Federal Governments\n \n \n \n Eligible Agencies of the Federal Government\n \n \n U.S. Territory or Possession\n \n \n \n \n \n Other\n \n \n \n Independent School Districts\n \n \n Public Housing Authorities/Indian Housing Authorities\n \n \n Native American Tribal Organizations (other than Federally recognized tribal governments)\n \n \n Faith-based or Community-based Organizations\n \n \n Regional Organizations\n \n \n \n \n Foreign Organizations\n \n \n \n Non-domestic (non-U.S.) Entities (Foreign Organization)\n \n are not\n \n eligible to apply.\n \n \n \n \n Non-domestic (non-U.S.) components of U.S. Organizations\n \n are not\n \n eligible to apply.\n \n \n \n \n Foreign components, as\n \n defined in the NIH Grants Policy Statement\n \n ,\n \n are\n \n allowed.\n \n \n \n Required Registrations\n \n \n Applicant organizations\n \n \n \n Applicant organizations must complete and maintain the following registrations as described in the\n \n How to Apply- Application Guide\n \n to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference\n \n NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications\n \n for additional information.\n \n \n \n \n System for Award Management (SAM)\n \n – Applicants must complete and maintain an active registration,\n \n which requires renewal at least annually\n \n . The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.\n \n \n \n NATO Commercial and Government Entity (NCAGE) Code\n \n – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.\n \n \n Unique Entity Identifier (UEI) - A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.\n \n \n \n \n \n eRA Commons\n \n - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their Grants.gov registration; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.\n \n \n \n Grants.gov\n \n – Applicants must have an active SAM registration in order to complete the Grants.gov registration.\n \n \n \n \n Program Directors/Principal Investigators (PD(s)/PI(s))\n \n \n \n All PD(s)/PI(s) must have an eRA Commons account. \_PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.\n \n \n \n Eligible Individuals (Program Director/Principal Investigator)\n \n Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support.\n \n \n For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the\n \n How to Apply - Application Guide\n \n .\n \n \n \n \n An NIH intramural scientist may not serve as the PD/PI of an NCDDG but may participate as a research collaborator or consultant (see\n \n \n \n Section IV.7\n \n \n \n for more information).\n \n \n \n \n 2. Cost Sharing\n \n \n This NOFO does not require cost sharing as defined in the\n \n NIH Grants Policy Statement\n \n \n Section 1.2- Definitions of Terms.\n \n \n \n \n \n 3. Additional Information on Eligibility\n \n \n Number of Applications\n \n \n \n \n Applicant organizations may submit more than one application, provided that each application is scientifically distinct.\n \n \n The NIH will not accept duplicate or highly overlapping applications under review at the same time per\n \n NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application\n \n . This means that the NIH will not accept:\n \n \n \n A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.\n \n \n A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.\n \n \n An application that has substantial overlap with another application pending appeal of initial peer review (see\n \n NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications\n \n )."
- source_sentence: >-
Can an organization submit multiple applications for the RFA-HL-26-011
opportunity, and what conditions must be met for these applications?
sentences:
- "PAR-25-378: Intervention Research to Improve Native American Health (R34 Clinical Trial Optional) Section VI. Award Administration Information\n \n \n \n \n 1. Award Notices\n \n \n A Notice of Award (NoA) is the official authorizing document notifying the applicant that an award has been made and that funds may be requested from the designated HHS payment system or office. The NoA is signed by the Grants Management Officer and emailed to the recipient’s business official.\n \n \n In accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.\n \n \n Recipients must comply with any funding restrictions described in\n \n Section IV.6. Funding Restrictions\n \n . Any pre-award costs incurred before receipt of the NoA are at the applicant's own risk. For more information on the Notice of Award, please refer to the\n \n NIH Grants Policy Statement Section 5. The Notice of Award\n \n and NIH Grants & Funding website, see\n \n Award Process.\n \n \n \n \n \n Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.\n \n \n ClinicalTrials.gov: If an award provides for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the \"responsible party\" must register and submit results information for certain “applicable clinical trials” on the ClinicalTrials.gov Protocol Registration and Results System Information Website (\n \n https://register.clinicaltrials.gov\n \n ). NIH expects registration and results reporting of all trials whether required under the law or not. For more information, see\n \n https://grants.nih.gov/policy/clinical-trials/reporting/index.htm\n \n \n \n Institutional Review Board or Independent Ethics Committee Approval: Recipient institutions must ensure that all protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.\n \n \n Data and Safety Monitoring Requirements: The NIH policy for data and safety monitoring requires oversight and monitoring of all NIH-conducted or -supported human biomedical and behavioral intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. Further information concerning these requirements is found at http://grants.nih.gov/grants/policy/hs/data_safety.htm and in the application instructions (SF424 (R&R) and PHS 398).\n \n \n Investigational New Drug or Investigational Device Exemption Requirements: Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).\n \n \n \n \n 2. Administrative and National Policy Requirements\n \n \n The following Federal wide and HHS-specific policy requirements apply to awards funded through NIH:\n \n \n \n The rules listed at\n \n 2 CFR Part 200\n \n , Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards.\n \n \n All NIH grant and cooperative agreement awards include the\n \n NIH Grants Policy Statement\n \n as part of the terms and conditions in the Notice of Award (NoA). The NoA includes the requirements of this NOFO. For these terms of award, see the\n \n NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General\n \n and\n \n Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Recipients, and Activities\n \n .\n \n \n If a recipient receives an award, the recipient must follow all applicable nondiscrimination laws. The recipient agrees to this when registering in SAM.gov. The recipient must also submit an Assurance of Compliance (\n \n HHS-690\n \n ). To learn more, see the\n \n Laws and Regulations Enforced by the\_HHS Office for Civil Rights website\n \n .\n \n \n HHS recognizes that NIH research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this NOFO.\n \n \n \n \n \n All federal statutes and regulations relevant to federal financial assistance, including those highlighted in\n \n NIH Grants Policy Statement Section 4 Public Policy Requirements, Objectives and Other Appropriation Mandates.\n \n \n \n Recipients are responsible for ensuring that their activities comply with all applicable federal regulations.\_ NIH may terminate awards under certain circumstances.\_ See\n \n 2 CFR Part 200.340 Termination\n \n and\n \n NIH Grants Policy Statement Section 8.5.2 Remedies for Noncompliance or Enforcement Actions: Suspension, Termination, and Withholding of Support\n \n .\n \n \n Successful recipients under this NOFO agree that:\n \n \n Where the award funding involves implementing, acquiring, or upgrading health IT for activities by any funded entity, recipients and subrecipient(s) are required to: Use health IT that meets standards and implementation specifications adopted in 45 CFR part 170, Subpart B, if such standards and implementation specifications can support the activity.\_ Visit\n \n https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-D/part-170/subpart-B\n \n to learn more.\n \n \n Where the award funding involves implementing, acquiring, or upgrading health IT for activities by eligible clinicians in ambulatory settings, or hospitals, eligible under Sections 4101, 4102, and 4201 of the HITECH Act, use health IT certified under the ONC Health IT Certification Program if certified technology can support the activity. Visit\n \n https://www.healthit.gov/topic/certification-ehrs/certification-health-it\n \n to learn more.\n \n \n Pursuant to the Cybersecurity Act of 2015, Div. N, § 405, Pub. Law 114-113, 6 USC § 1533(d), the HHS Secretary has established a common set of voluntary, consensus-based, and industry-led guidelines, best practices, methodologies, procedures, and processes.\n \n \n Successful recipients under this NOFO agree that:\n \n \n When recipients, subrecipients, or third-party entities have:\n \n \n 1) ongoing and consistent access to HHS owned or operated information or operational technology systems; and\n \n \n 2) receive, maintain, transmit, store, access, exchange, process, or utilize personal identifiable information (PII) or personal health information (PHI) obtained from the awarding HHS agency for the purposes of executing the award.\n \n \n Recipients shall develop plans and procedures, modeled after the\n \n NIST Cybersecurity framework\n \n , to protect HHS systems and data. Please refer to\n \n NIH Post-Award Monitoring and Reporting\n \n for additional information.\n \n \n \n Cooperative Agreement Terms and Conditions of Award\n \n Not Applicable\n \n \n \n 3. Data Management and Sharing\n \n Consistent with the 2023 NIH Policy for Data Management and Sharing, when data management and sharing is applicable to the award, recipients will be required to adhere to the Data Management and Sharing requirements as outlined in the\n \n NIH Grants Policy Statement\n \n . Upon the approval of a Data Management and Sharing Plan, it is required for recipients to implement the plan as described.\n \n \n \n \n 4. Reporting\n \n \n When multiple years are involved, recipients will be required to submit the\n \n Research Performance Progress Report (RPPR)\n \n annually and financial statements as required in the\n \n NIH Grants Policy Statement Section 8.4.1 Reporting.\n \n To learn more about post-award monitoring and reporting, see the NIH Grants & Funding website, see\n \n Post-Award Monitoring and Reporting\n \n .\n \n \n \n \n A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the\n \n NIH Grants Policy Statement Section 8.6 Closeout\n \n . NIH NOFOs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 2 CFR Part 200.301."
- >-
PAR-25-378: Intervention Research to Improve Native American Health (R34
Clinical Trial Optional) Section II. Award Information
Funding Instrument
Grant: A financial assistance mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.
Application Types Allowed
New
Resubmission
The
OER Glossary
and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
Clinical Trial?
Optional: Accepting applications that either propose or do not propose clinical trial(s).
Need help determining whether you are doing a clinical trial?
Funds Available and Anticipated Number of Awards
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Award Budget
Applicants may request direct costs of up to $450,000 for three years. Although variations from year to year are permissible, in no case may any year be more than $225,000 in direct costs, and total direct costs for the entire project period may not exceed $450,000.
Award Project Period
The scope of the proposed project should determine the project period. The maximum project period is 3 years.
This variable defines that we need to start a new row.
NIH grants policies as described in the
NIH Grants Policy Statement
will apply to the applications submitted and awards made from this NOFO.
- "RFA-HL-26-011: Leadership and Coordination Center (LACC) for the MACS/WIHS Combined Cohort Study (MWCCS) (U01 Clinical Trials Not Allowed) Section III. Eligibility Information\n \n \n \n \n 1. Eligible Applicants\n \n \n \n Eligible Organizations\n \n Higher Education Institutions\n \n \n \n Public/State Controlled Institutions of Higher Education\n \n \n Private Institutions of Higher Education\n \n \n \n The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:\n \n \n \n Hispanic-serving Institutions\n \n \n Historically Black Colleges and Universities (HBCUs)\n \n \n Tribally Controlled Colleges and Universities (TCCUs)\n \n \n Alaska Native and Native Hawaiian Serving Institutions\n \n \n Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)\n \n \n \n Nonprofits Other Than Institutions of Higher Education\n \n \n \n Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)\n \n \n Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)\n \n \n \n For-Profit Organizations\n \n \n \n Small Businesses\n \n \n For-Profit Organizations (Other than Small Businesses)\n \n \n \n Local Governments\n \n \n \n State Governments\n \n \n County Governments\n \n \n City or Township Governments\n \n \n Special District Governments\n \n \n Indian/Native American Tribal Governments (Federally Recognized)\n \n \n Indian/Native American Tribal Governments (Other than Federally Recognized).\n \n \n \n \n \n Federal Governments\n \n \n \n Eligible Agencies of the Federal Government\n \n \n U.S. Territory or Possession\n \n \n \n \n \n Other\n \n \n \n Independent School Districts\n \n \n Public Housing Authorities/Indian Housing Authorities\n \n \n Native American Tribal Organizations (other than Federally recognized tribal governments)\n \n \n Faith-based or Community-based Organizations\n \n \n Regional Organizations\n \n \n \n \n Foreign Organizations\n \n \n \n Non-domestic (non-U.S.) Entities (Foreign Organizations)\n \n are not\n \n eligible to apply.\n \n \n \n \n Non-domestic (non-U.S.) components of U.S. Organizations\n \n are not\n \n eligible to apply.\n \n \n \n \n Foreign components, as\n \n defined in the NIH Grants Policy Statement\n \n ,\n \n are not\n \n allowed.\n \n \n \n Required Registrations\n \n \n Applicant Organizations\n \n \n \n Applicant organizations must complete and maintain the following registrations as described in the How to Apply- Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference the\n \n NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications\n \n for additional information.\n \n \n \n \n System for Award Management (SAM) –\n \n Applicants must complete and maintain an active registration,\n \n which requires renewal at least annually\n \n . The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.\n \n \n \n NATO Commercial and Government Entity (NCAGE) Code\n \n – Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.\n \n \n Unique Entity Identifier (UEI) - A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.\n \n \n \n \n \n eRA Commons\n \n - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their\_Grants.gov registrations; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.\n \n \n \n Grants.gov\n \n – Applicants must have an active SAM registration in order to complete the Grants.gov registration.\n \n \n \n \n Program Directors/Principal Investigators (PD(s)/PI(s))\n \n \n \n All PD(s)/PI(s) must have an eRA Commons account. \_PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.\n \n \n \n Eligible Individuals (Program Director/Principal Investigator)\n \n Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support.\n \n \n For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply-Application Guide.\n \n \n \n \n A multiple PI (mPI) leadership structure is required. The LACC mPI team should include individuals with demonstrated deep knowledge of, and familiarity with, the MWCCS. In addition, the team should include at least one clinician with experience in clinical care of patients living with HIV and/or relevant comorbidities, as well as one or more individuals with epidemiologic cohort study leadership experience.Individuals may not apply to be an mPI of both the LACC and Data Analysis and Sharing Center (DASC) (\n \n RFA-HL-26-010\n \n ). Applications without an mPI leadership structure will be considered incomplete and will not proceed to peer review.\n \n \n \n \n 2. Cost Sharing\n \n \n This NOFO does not require cost sharing as defined in the\n \n NIH Grants Policy Statement Section 1.2 Definition of Terms\n \n .\n \n \n \n \n 3. Additional Information on Eligibility\n \n \n Number of Applications\n \n \n \n \n Applicant organizations may submit more than one application, provided that each application is scientifically distinct.\n \n \n The NIH will not accept duplicate or highly overlapping applications under review at the same time, per\n \n NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application\n \n . This means that the NIH will not accept:\n \n \n \n A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.\n \n \n A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.\n \n \n An application that has substantial overlap with another application pending appeal of initial peer review (see\n \n NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications\n \n )."
- source_sentence: >-
What is the purpose of the funding opportunity RFA-DK-26-007 titled
"Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes
Clinical Studies"?
sentences:
- Department of Health and Human Services
- >-
RFA-DK-26-007: Collaborative Research Using Biosamples and/or Data from
Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed) Part
1. Overview Information
Participating Organization(s)
National Institutes of Health (
NIH
)
Components of Participating Organizations
National Institute of Diabetes and Digestive and Kidney Diseases (
NIDDK
)
Office of The Director, National Institutes of Health (
OD
)
Funding Opportunity Title
Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)
Activity Code
R01
Research Project Grant
Announcement Type
Reissue of
RFA-DK-22-021
Related Notices
April 4, 2024
- Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice
NOT-OD-24-084
.
August 31, 2022
- Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice
NOT-OD-22-198
.
August 5, 2022
- Implementation Details for the NIH Data Management and Sharing Policy. See Notice
NOT-OD-22-189
.
Funding Opportunity Number (FON)
RFA-DK-26-007
Companion Funding Opportunity
None
Number of Applications
See
Section III. 3. Additional Information on Eligibility
.
Assistance Listing Number(s)
93.847
Funding Opportunity Purpose
This Notice of Funding Opportunity (NOFO) invites applications for studies of type 1 diabetes etiology and pathogenesis using data and samples from clinical trials and studies. This opportunity is intended to fund investigative teams collaborating to answer important questions about disease mechanisms leading to improved delay and durable prevention of type 1 diabetes. This NOFO is associated with the Special Diabetes Program (
https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program
) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.
Funding Opportunity Goal(s)
To promote extramural basic and clinical biomedical research that improves the understanding of the mechanisms underlying disease and leads to improved preventions, diagnosis, and treatment of diabetes, digestive, and kidney diseases. Programmatic areas within the National Institute of Diabetes and Digestive and Kidney Diseases include diabetes, digestive, endocrine, hematologic, liver, metabolic, nephrologic, nutrition, obesity, and urologic diseases.
This variable defines that we need to start a new row.
- >-
RFA-DK-26-007: Collaborative Research Using Biosamples and/or Data from
Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed) Part
1. Overview Information
Participating Organization(s)
National Institutes of Health (
NIH
)
Components of Participating Organizations
National Institute of Diabetes and Digestive and Kidney Diseases (
NIDDK
)
Office of The Director, National Institutes of Health (
OD
)
Funding Opportunity Title
Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)
Activity Code
R01
Research Project Grant
Announcement Type
Reissue of
RFA-DK-22-021
Related Notices
April 4, 2024
- Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice
NOT-OD-24-084
.
August 31, 2022
- Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice
NOT-OD-22-198
.
August 5, 2022
- Implementation Details for the NIH Data Management and Sharing Policy. See Notice
NOT-OD-22-189
.
Funding Opportunity Number (FON)
RFA-DK-26-007
Companion Funding Opportunity
None
Number of Applications
See
Section III. 3. Additional Information on Eligibility
.
Assistance Listing Number(s)
93.847
Funding Opportunity Purpose
This Notice of Funding Opportunity (NOFO) invites applications for studies of type 1 diabetes etiology and pathogenesis using data and samples from clinical trials and studies. This opportunity is intended to fund investigative teams collaborating to answer important questions about disease mechanisms leading to improved delay and durable prevention of type 1 diabetes. This NOFO is associated with the Special Diabetes Program (
https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program
) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.
Funding Opportunity Goal(s)
To promote extramural basic and clinical biomedical research that improves the understanding of the mechanisms underlying disease and leads to improved preventions, diagnosis, and treatment of diabetes, digestive, and kidney diseases. Programmatic areas within the National Institute of Diabetes and Digestive and Kidney Diseases include diabetes, digestive, endocrine, hematologic, liver, metabolic, nephrologic, nutrition, obesity, and urologic diseases.
This variable defines that we need to start a new row.
pipeline_tag: sentence-similarity
library_name: sentence-transformers
metrics:
- cosine_accuracy@1
- cosine_accuracy@3
- cosine_accuracy@5
- cosine_accuracy@10
- cosine_precision@1
- cosine_precision@3
- cosine_precision@5
- cosine_precision@10
- cosine_recall@1
- cosine_recall@3
- cosine_recall@5
- cosine_recall@10
- cosine_ndcg@10
- cosine_mrr@10
- cosine_map@100
model-index:
- name: SentenceTransformer based on Snowflake/snowflake-arctic-embed-l
results:
- task:
type: information-retrieval
name: Information Retrieval
dataset:
name: Unknown
type: unknown
metrics:
- type: cosine_accuracy@1
value: 0.875
name: Cosine Accuracy@1
- type: cosine_accuracy@3
value: 1
name: Cosine Accuracy@3
- type: cosine_accuracy@5
value: 1
name: Cosine Accuracy@5
- type: cosine_accuracy@10
value: 1
name: Cosine Accuracy@10
- type: cosine_precision@1
value: 0.875
name: Cosine Precision@1
- type: cosine_precision@3
value: 0.3333333333333333
name: Cosine Precision@3
- type: cosine_precision@5
value: 0.20000000000000004
name: Cosine Precision@5
- type: cosine_precision@10
value: 0.10000000000000002
name: Cosine Precision@10
- type: cosine_recall@1
value: 0.875
name: Cosine Recall@1
- type: cosine_recall@3
value: 1
name: Cosine Recall@3
- type: cosine_recall@5
value: 1
name: Cosine Recall@5
- type: cosine_recall@10
value: 1
name: Cosine Recall@10
- type: cosine_ndcg@10
value: 0.9484108127976215
name: Cosine Ndcg@10
- type: cosine_mrr@10
value: 0.9305555555555555
name: Cosine Mrr@10
- type: cosine_map@100
value: 0.9305555555555555
name: Cosine Map@100
SentenceTransformer based on Snowflake/snowflake-arctic-embed-l
This is a sentence-transformers model finetuned from Snowflake/snowflake-arctic-embed-l. It maps sentences & paragraphs to a 1024-dimensional dense vector space and can be used for semantic textual similarity, semantic search, paraphrase mining, text classification, clustering, and more.
Model Details
Model Description
- Model Type: Sentence Transformer
- Base model: Snowflake/snowflake-arctic-embed-l
- Maximum Sequence Length: 512 tokens
- Output Dimensionality: 1024 dimensions
- Similarity Function: Cosine Similarity
Model Sources
- Documentation: Sentence Transformers Documentation
- Repository: Sentence Transformers on GitHub
- Hugging Face: Sentence Transformers on Hugging Face
Full Model Architecture
SentenceTransformer(
(0): Transformer({'max_seq_length': 512, 'do_lower_case': False}) with Transformer model: BertModel
(1): Pooling({'word_embedding_dimension': 1024, 'pooling_mode_cls_token': True, 'pooling_mode_mean_tokens': False, 'pooling_mode_max_tokens': False, 'pooling_mode_mean_sqrt_len_tokens': False, 'pooling_mode_weightedmean_tokens': False, 'pooling_mode_lasttoken': False, 'include_prompt': True})
(2): Normalize()
)
Usage
Direct Usage (Sentence Transformers)
First install the Sentence Transformers library:
pip install -U sentence-transformers
Then you can load this model and run inference.
from sentence_transformers import SentenceTransformer
# Download from the 🤗 Hub
model = SentenceTransformer("christinemahler/aie5-midter-new")
# Run inference
sentences = [
'What is the purpose of the funding opportunity RFA-DK-26-007 titled "Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies"?',
'RFA-DK-26-007: Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed) Part 1. Overview Information\n \n \n \n Participating Organization(s)\n \n National Institutes of Health (\n \n NIH\n \n )\n \n \n \n Components of Participating Organizations\n \n National Institute of Diabetes and Digestive and Kidney Diseases (\n \n NIDDK\n \n )\n \n \n Office of The Director, National Institutes of Health (\n \n OD\n \n )\n \n \n \n Funding Opportunity Title\n \n Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)\n \n \n \n Activity Code\n \n \n R01\n \n Research Project Grant\n \n \n \n Announcement Type\n Reissue of\n \n RFA-DK-22-021\n \n \n \n \n Related Notices\n \n \n \n April 4, 2024\n \n - Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice\n \n NOT-OD-24-084\n \n .\n \n \n \n August 31, 2022\n \n - Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice\n \n NOT-OD-22-198\n \n .\n \n \n \n August 5, 2022\n \n - Implementation Details for the NIH Data Management and Sharing Policy. See Notice\n \n NOT-OD-22-189\n \n .\n \n \n \n \n Funding Opportunity Number (FON)\n \n RFA-DK-26-007\n \n \n \n Companion Funding Opportunity\n None\n \n \n Number of Applications\n \n See\n \n Section III. 3. Additional Information on Eligibility\n \n .\n \n \n \n Assistance Listing Number(s)\n 93.847\n \n \n Funding Opportunity Purpose\n \n This Notice of Funding Opportunity (NOFO) invites applications for studies of type 1 diabetes etiology and pathogenesis using data and samples from clinical trials and studies. This opportunity is intended to fund investigative teams collaborating to answer important questions about disease mechanisms leading to improved delay and durable prevention of type 1 diabetes. This NOFO is associated with the Special Diabetes Program (\n \n https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program\n \n ) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.\n \n \n \n \n \n \n \n Funding Opportunity Goal(s)\n \n To promote extramural basic and clinical biomedical research that improves the understanding of the mechanisms underlying disease and leads to improved preventions, diagnosis, and treatment of diabetes, digestive, and kidney diseases. Programmatic areas within the National Institute of Diabetes and Digestive and Kidney Diseases include diabetes, digestive, endocrine, hematologic, liver, metabolic, nephrologic, nutrition, obesity, and urologic diseases.\n \n This variable defines that we need to start a new row.',
'RFA-DK-26-007: Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed) Part 1. Overview Information\n \n \n \n Participating Organization(s)\n \n National Institutes of Health (\n \n NIH\n \n )\n \n \n \n Components of Participating Organizations\n \n National Institute of Diabetes and Digestive and Kidney Diseases (\n \n NIDDK\n \n )\n \n \n Office of The Director, National Institutes of Health (\n \n OD\n \n )\n \n \n \n Funding Opportunity Title\n \n Collaborative Research Using Biosamples and/or Data from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)\n \n \n \n Activity Code\n \n \n R01\n \n Research Project Grant\n \n \n \n Announcement Type\n Reissue of\n \n RFA-DK-22-021\n \n \n \n \n Related Notices\n \n \n \n April 4, 2024\n \n - Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice\n \n NOT-OD-24-084\n \n .\n \n \n \n August 31, 2022\n \n - Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice\n \n NOT-OD-22-198\n \n .\n \n \n \n August 5, 2022\n \n - Implementation Details for the NIH Data Management and Sharing Policy. See Notice\n \n NOT-OD-22-189\n \n .\n \n \n \n \n Funding Opportunity Number (FON)\n \n RFA-DK-26-007\n \n \n \n Companion Funding Opportunity\n None\n \n \n Number of Applications\n \n See\n \n Section III. 3. Additional Information on Eligibility\n \n .\n \n \n \n Assistance Listing Number(s)\n 93.847\n \n \n Funding Opportunity Purpose\n \n This Notice of Funding Opportunity (NOFO) invites applications for studies of type 1 diabetes etiology and pathogenesis using data and samples from clinical trials and studies. This opportunity is intended to fund investigative teams collaborating to answer important questions about disease mechanisms leading to improved delay and durable prevention of type 1 diabetes. This NOFO is associated with the Special Diabetes Program (\n \n https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program\n \n ) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.\n \n \n \n \n \n \n \n Funding Opportunity Goal(s)\n \n To promote extramural basic and clinical biomedical research that improves the understanding of the mechanisms underlying disease and leads to improved preventions, diagnosis, and treatment of diabetes, digestive, and kidney diseases. Programmatic areas within the National Institute of Diabetes and Digestive and Kidney Diseases include diabetes, digestive, endocrine, hematologic, liver, metabolic, nephrologic, nutrition, obesity, and urologic diseases.\n \n This variable defines that we need to start a new row.',
]
embeddings = model.encode(sentences)
print(embeddings.shape)
# [3, 1024]
# Get the similarity scores for the embeddings
similarities = model.similarity(embeddings, embeddings)
print(similarities.shape)
# [3, 3]
Evaluation
Metrics
Information Retrieval
- Evaluated with
InformationRetrievalEvaluator
| Metric | Value |
|---|---|
| cosine_accuracy@1 | 0.875 |
| cosine_accuracy@3 | 1.0 |
| cosine_accuracy@5 | 1.0 |
| cosine_accuracy@10 | 1.0 |
| cosine_precision@1 | 0.875 |
| cosine_precision@3 | 0.3333 |
| cosine_precision@5 | 0.2 |
| cosine_precision@10 | 0.1 |
| cosine_recall@1 | 0.875 |
| cosine_recall@3 | 1.0 |
| cosine_recall@5 | 1.0 |
| cosine_recall@10 | 1.0 |
| cosine_ndcg@10 | 0.9484 |
| cosine_mrr@10 | 0.9306 |
| cosine_map@100 | 0.9306 |
Training Details
Training Dataset
Unnamed Dataset
- Size: 216 training samples
- Columns:
sentence_0andsentence_1 - Approximate statistics based on the first 216 samples:
sentence_0 sentence_1 type string string details - min: 19 tokens
- mean: 34.9 tokens
- max: 59 tokens
- min: 8 tokens
- mean: 377.44 tokens
- max: 512 tokens
- Samples:
sentence_0 sentence_1 What initiatives is the Department of Health and Human Services pursuing under opportunity ID [insert ID] to improve public health outcomes?Department of Health and Human ServicesHow does the title of opportunity ID [insert ID] align with the strategic goals of the Department of Health and Human Services?Department of Health and Human ServicesWhat are the main goals of the funding opportunity titled "Laboratory Flexible Funding Model (LFFM)" under opportunity ID RFA-FD-25-007?RFA-FD-25-007: Laboratory Flexible Funding Model (LFFM) Part 1. Overview Information
Participating Organization(s)
U.S. Food and Drug Administration (
FDA
)
NOTE: The policies, guidelines, terms, and conditions stated in this Notice of Funding Opportunity (NOFO) may differ from those used by the NIH. Where this NOFO provides specific written guidance that may differ from the general guidance provided in the grant application form, please follow the instructions given in this NOFO.
The FDA does not follow the NIH Page Limitation Guidelines or the NIH Review Criteria. Applicants are encouraged to consult with FDA Agency Contacts for additional information regarding page limits and the FDA Objective Review Process.
Components of Participating Organizations
FOOD AND DRUG ADMINISTRATION (
FDA
)
Funding Opportunity Title
Laboratory Flexible Funding Model (LFFM)
... - Loss:
MatryoshkaLosswith these parameters:{ "loss": "MultipleNegativesRankingLoss", "matryoshka_dims": [ 768, 512, 256, 128, 64 ], "matryoshka_weights": [ 1, 1, 1, 1, 1 ], "n_dims_per_step": -1 }
Training Hyperparameters
Non-Default Hyperparameters
eval_strategy: stepsper_device_train_batch_size: 10per_device_eval_batch_size: 10num_train_epochs: 10multi_dataset_batch_sampler: round_robin
All Hyperparameters
Click to expand
overwrite_output_dir: Falsedo_predict: Falseeval_strategy: stepsprediction_loss_only: Trueper_device_train_batch_size: 10per_device_eval_batch_size: 10per_gpu_train_batch_size: Noneper_gpu_eval_batch_size: Nonegradient_accumulation_steps: 1eval_accumulation_steps: Nonetorch_empty_cache_steps: Nonelearning_rate: 5e-05weight_decay: 0.0adam_beta1: 0.9adam_beta2: 0.999adam_epsilon: 1e-08max_grad_norm: 1num_train_epochs: 10max_steps: -1lr_scheduler_type: linearlr_scheduler_kwargs: {}warmup_ratio: 0.0warmup_steps: 0log_level: passivelog_level_replica: warninglog_on_each_node: Truelogging_nan_inf_filter: Truesave_safetensors: Truesave_on_each_node: Falsesave_only_model: Falserestore_callback_states_from_checkpoint: Falseno_cuda: Falseuse_cpu: Falseuse_mps_device: Falseseed: 42data_seed: Nonejit_mode_eval: Falseuse_ipex: Falsebf16: Falsefp16: Falsefp16_opt_level: O1half_precision_backend: autobf16_full_eval: Falsefp16_full_eval: Falsetf32: Nonelocal_rank: 0ddp_backend: Nonetpu_num_cores: Nonetpu_metrics_debug: Falsedebug: []dataloader_drop_last: Falsedataloader_num_workers: 0dataloader_prefetch_factor: Nonepast_index: -1disable_tqdm: Falseremove_unused_columns: Truelabel_names: Noneload_best_model_at_end: Falseignore_data_skip: Falsefsdp: []fsdp_min_num_params: 0fsdp_config: {'min_num_params': 0, 'xla': False, 'xla_fsdp_v2': False, 'xla_fsdp_grad_ckpt': False}fsdp_transformer_layer_cls_to_wrap: Noneaccelerator_config: {'split_batches': False, 'dispatch_batches': None, 'even_batches': True, 'use_seedable_sampler': True, 'non_blocking': False, 'gradient_accumulation_kwargs': None}deepspeed: Nonelabel_smoothing_factor: 0.0optim: adamw_torchoptim_args: Noneadafactor: Falsegroup_by_length: Falselength_column_name: lengthddp_find_unused_parameters: Noneddp_bucket_cap_mb: Noneddp_broadcast_buffers: Falsedataloader_pin_memory: Truedataloader_persistent_workers: Falseskip_memory_metrics: Trueuse_legacy_prediction_loop: Falsepush_to_hub: Falseresume_from_checkpoint: Nonehub_model_id: Nonehub_strategy: every_savehub_private_repo: Nonehub_always_push: Falsegradient_checkpointing: Falsegradient_checkpointing_kwargs: Noneinclude_inputs_for_metrics: Falseinclude_for_metrics: []eval_do_concat_batches: Truefp16_backend: autopush_to_hub_model_id: Nonepush_to_hub_organization: Nonemp_parameters:auto_find_batch_size: Falsefull_determinism: Falsetorchdynamo: Noneray_scope: lastddp_timeout: 1800torch_compile: Falsetorch_compile_backend: Nonetorch_compile_mode: Nonedispatch_batches: Nonesplit_batches: Noneinclude_tokens_per_second: Falseinclude_num_input_tokens_seen: Falseneftune_noise_alpha: Noneoptim_target_modules: Nonebatch_eval_metrics: Falseeval_on_start: Falseuse_liger_kernel: Falseeval_use_gather_object: Falseaverage_tokens_across_devices: Falseprompts: Nonebatch_sampler: batch_samplermulti_dataset_batch_sampler: round_robin
Training Logs
| Epoch | Step | cosine_ndcg@10 |
|---|---|---|
| 1.0 | 22 | 0.8768 |
| 2.0 | 44 | 0.9484 |
| 2.2727 | 50 | 0.9330 |
| 3.0 | 66 | 0.9276 |
| 4.0 | 88 | 0.9484 |
| 4.5455 | 100 | 0.9330 |
| 5.0 | 110 | 0.9638 |
| 6.0 | 132 | 0.9638 |
| 6.8182 | 150 | 0.9638 |
| 7.0 | 154 | 0.9638 |
| 8.0 | 176 | 0.9484 |
| 9.0 | 198 | 0.9484 |
| 9.0909 | 200 | 0.9484 |
| 10.0 | 220 | 0.9484 |
Framework Versions
- Python: 3.11.11
- Sentence Transformers: 3.3.1
- Transformers: 4.48.3
- PyTorch: 2.5.1+cu124
- Accelerate: 1.3.0
- Datasets: 3.3.2
- Tokenizers: 0.21.0
Citation
BibTeX
Sentence Transformers
@inproceedings{reimers-2019-sentence-bert,
title = "Sentence-BERT: Sentence Embeddings using Siamese BERT-Networks",
author = "Reimers, Nils and Gurevych, Iryna",
booktitle = "Proceedings of the 2019 Conference on Empirical Methods in Natural Language Processing",
month = "11",
year = "2019",
publisher = "Association for Computational Linguistics",
url = "https://arxiv.org/abs/1908.10084",
}
MatryoshkaLoss
@misc{kusupati2024matryoshka,
title={Matryoshka Representation Learning},
author={Aditya Kusupati and Gantavya Bhatt and Aniket Rege and Matthew Wallingford and Aditya Sinha and Vivek Ramanujan and William Howard-Snyder and Kaifeng Chen and Sham Kakade and Prateek Jain and Ali Farhadi},
year={2024},
eprint={2205.13147},
archivePrefix={arXiv},
primaryClass={cs.LG}
}
MultipleNegativesRankingLoss
@misc{henderson2017efficient,
title={Efficient Natural Language Response Suggestion for Smart Reply},
author={Matthew Henderson and Rami Al-Rfou and Brian Strope and Yun-hsuan Sung and Laszlo Lukacs and Ruiqi Guo and Sanjiv Kumar and Balint Miklos and Ray Kurzweil},
year={2017},
eprint={1705.00652},
archivePrefix={arXiv},
primaryClass={cs.CL}
}